BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11170139)

  • 1. Targeted destruction of androgen-sensitive and -insensitive prostate cancer cells and xenografts through luteinizing hormone receptors.
    Leuschner C; Enright FM; Melrose PA; Hansel W
    Prostate; 2001 Feb; 46(2):116-25. PubMed ID: 11170139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted destruction of prostate cancer cells and xenografts by lytic peptide-betaLH conjugates.
    Hansel W; Leuschner C; Gawrońska B; Enright F
    Reprod Biol; 2001 Jul; 1(1):20-32. PubMed ID: 14666172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo.
    Leuschner C; Enright FM; Gawronska B; Hansel W
    Breast Cancer Res Treat; 2003 Mar; 78(1):17-27. PubMed ID: 12611453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors.
    Leuschner C; Enright FM; Gawronska-Kozak B; Hansel W
    Prostate; 2003 Sep; 56(4):239-49. PubMed ID: 12858351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo.
    Gawronska B; Leuschner C; Enright FM; Hansel W
    Gynecol Oncol; 2002 Apr; 85(1):45-52. PubMed ID: 11925119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting breast and prostate cancers through their hormone receptors.
    Leuschner C; Hansel W
    Biol Reprod; 2005 Nov; 73(5):860-5. PubMed ID: 16033998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate.
    Bodek G; Rahman NA; Zaleska M; Soliymani R; Lankinen H; Hansel W; Huhtaniemi I; Ziecik AJ
    Breast Cancer Res Treat; 2003 May; 79(1):1-10. PubMed ID: 12779076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice.
    Bodek G; Vierre S; Rivero-Müller A; Huhtaniemi I; Ziecik AJ; Rahman NA
    Neoplasia; 2005 May; 7(5):497-508. PubMed ID: 15967102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy for adrenocortical tumors in transgenic mice through their LH receptor by Hecate-human chorionic gonadotropin beta conjugate.
    Vuorenoja S; Rivero-Müller A; Ziecik AJ; Huhtaniemi I; Toppari J; Rahman NA
    Endocr Relat Cancer; 2008 Jun; 15(2):635-48. PubMed ID: 18509010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted destruction of normal and cancer cells through lutropin/choriogonadotropin receptors using Hecate-betaCG conjugate.
    Zaleska M; Bodek G; Jana B; Hansel W; Ziecik AJ
    Exp Clin Endocrinol Diabetes; 2003 May; 111(3):146-53. PubMed ID: 12784188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth repression in diethylstilbestrol/dimethylbenz[a]anthracene-induced rat mammary gland tumor using Hecate-CGbeta conjugate.
    Zaleska M; Waclawik A; Bodek G; Zezula-Szpyra A; Li X; Janowski T; Hansel WH; Rahman NA; Ziecik AJ
    Exp Biol Med (Maywood); 2004 Apr; 229(4):335-44. PubMed ID: 15044717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted ablation of prostate carcinoma cells through LH receptor using Hecate-CGbeta conjugate: functional characteristic and molecular mechanism of cell death pathway.
    Bodek G; Kowalczyk A; Waclawik A; Huhtaniemi I; Ziecik AJ
    Exp Biol Med (Maywood); 2005 Jun; 230(6):421-8. PubMed ID: 15956772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follicle-stimulating hormone promotes growth of human prostate cancer cell line-derived tumor xenografts.
    Oduwole OO; Poliandri A; Okolo A; Rawson P; Doroszko M; Chrusciel M; Rahman NA; Serrano de Almeida G; Bevan CL; Koechling W; Huhtaniemi IT
    FASEB J; 2021 Apr; 35(4):e21464. PubMed ID: 33724574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo.
    Hansel W; Enright F; Leuschner C
    Mol Cell Endocrinol; 2007 Jan; 260-262():183-9. PubMed ID: 17101210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of hecate-chorionic gonadotropin beta conjugate in therapy of lutenizing hormone receptor expressing gonadal somatic cell tumors.
    Rivero-Müller A; Vuorenoja S; Tuominen M; Wacławik A; Brokken LJ; Ziecik AJ; Huhtaniemi I; Rahman NA
    Mol Cell Endocrinol; 2007 Apr; 269(1-2):17-25. PubMed ID: 17363137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of luteinizing hormone receptor signaling in prostate cancer cells.
    Xiong S; Wang Q; Liu SV; Montgomery RB; Stanczyk FZ; Vallone JG; Merin NM; Pinski J
    Prostate; 2015 Feb; 75(2):141-50. PubMed ID: 25393079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR; Radulovic S; Groot K; Schally AV
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
    Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
    Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.